Mineralocorticoid Receptor Antagonism and Glucagon-Like Peptide 1 Receptor Agonism Have Direct Effects on Glomerular Cells to Reduce Glomerular Albumin Permeability in Diabetes (KIDNEY WEEK 2026) - Oct 2, 2026 - Abstract #TH-PO0372; Pres time: Oct 22, 2026; 10:00 AM - 12:00 PM; Location: Exhibit Hall A, Convention Center; "Isolated glomeruli were incubated with 10% rat plasma for 1 hour at 37°C, and treated with clinically relevant doses of atrasentan, empagliflozin, finerenone, lisinopril, semaglutide, angiopoietin-1 (positive control) or vehicle. Conclusion MR antagonism and GLP1 receptor agonism, by finerenone and semaglutide, both ameliorate the diabetes-induced increase in P s' alb , demonstrating a direct effect on the cells of the GFB in diabetes. Thus, a greater understanding of the mechanisms of glomerular protection mediated by these renoprotective compounds is needed to identify novel therapeutic strategies."
Chronic Kidney Disease • Diabetes • Diabetic Nephropathy • Metabolic Disorders • Nephrology • Renal Disease • Type 1 Diabetes Mellitus • ANGPT1
|
|
Michael Crompton; Holly Stowell-Connolly; Jack Mills; Patrick Wa Frost; Matthew J. Butler; Gavin Iain Welsh; Ross Lindsay; Ryan J. Nagao; Agnes M. Benardeau; Mette Viberg Østergaard; Rebecca R. Foster; Simon C. Satchell
|